PER-051-04已完成未知
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY AND EFFECTIVENESS OF THE ADDITION OF THE TREATMENT WITH MK-0431EN PATIENTS WITH DIABETES MELLITUS TYPE 2 WHO HAVE AN INAPPROPRIATE GLYCEMIC CONTROL WITH METFORMIN THERAPY.
MERCK SHARP & DOHME PERU S.R.L.,0 个研究点目标入组 0 人开始时间: 2004年8月12日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •a. The patient has type 2 diabetes mellitus.
- •b. The patient is between> 18 and <78 years of age.
- •c. The patient understands the study procedures and agrees to participate in the study by providing written informed consent.
- •d. The patient is not pregnant or breastfeeding and does not plan to become pregnant during the course of the study or during the post-study follow-up period.
排除标准
- •a. The patient has a history of type 1 diabetes mellitus or a history of ketoacidosis.
- •b. The patient needed insulin within the previous 8 weeks.
- •c. The patient is in a program to lose weight and is not in the maintenance phase.
- •d. The patient started a therapy with medication to lose weight.
研究者
相似试验
已完成
不适用
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SITAGLIPTINE AGAINST GLIPIZIDE IN PATIENTS WITH DIABETES MELLITUS TYPE 2 AND TERMINAL PHASE NEPHROPATHY THAT ARE SUBJECTED TO DIALYSIS AND HAVE AN INAPPROPRIATE GLYCEMIC CONTRO-E10 Insulin-dependent diabetes mellitus-E14 Unspecified diabetes mellitusInsulin-dependent diabetes mellitusUnspecified diabetes mellitusE10E14PER-038-08MERCK SHARP & DOHME PERU S.R.L.,
已完成
不适用
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SITAGLIPTIN AGAINST GLIPIZIDE IN PATIENTS WITH DIABETES MELLITUS TYPE 2 AND CHRONIC RENAL INSUFICIENCY THAT HAVE AN INAPPROPRIATE GLYCEMIC CONTRO-E10 Insulin-dependent diabetes mellitus-E14 Unspecified diabetes mellitusInsulin-dependent diabetes mellitusUnspecified diabetes mellitusE10E14PER-035-08MERCK SHARP & DOHME PERU S.R.L.,
未知
不适用
OMNEON ™-024-E11 Non-insulin-dependent diabetes mellitusNon-insulin-dependent diabetes mellitusE11PER-023-13Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,
已完成
不适用
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE ADDITION OF MK-0431 IN PATIENTS WITH DIABETES MELLITUS TYPE 2 WHO HAVE AN UNPROTECTED GLUCEMIC CONTROL WITH PIOGLITAZONE THERAPYPER-054-04MERCK SHARP & DOHME PERU S.R.L.,
已完成
不适用
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MONOTHERAPY WITH MK-0431 IN PATIENTS WITH DIABETES MELLITUS TYPE 2 WHO HAVE AN INAPPROPRIATE GLYCEMIC CONTROL.-E119 Non-insulin-dependent diabetes mellitus, without complicationsNon-insulin-dependent diabetes mellitus, without complicationsE119PER-050-04MERCK SHARP & DOHME PERU S.R.L.,